All In Biotech

Drug Trial Radar · NCT05170048

Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

A Phase 2, Parallel, Randomized, Open-label, Controlled Study of EG-301 150 mg Daily in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Evergreen Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD). Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are: 1. AREDS2 supplements (Control Group, N=30) 2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)

Conditions

  • Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)

Interventions

  • EG-301Drug

    The investigation drug, EG-301 Tablets 150mg, is for oral use.

  • AREDS2 supplementsDietary supplement

    AREDS2 supplement is the stand of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events Assessment using CTCAE v5.0Time frame: Evaluation in 26 weeks treatment period, and 4 weeks safety follow up period.
  2. GA lesion size changeTime frame: From baseline to Week 26 treatment period
  3. Overall retinal sensitivityTime frame: From baseline to Week 26 treatment period
  4. BCVA in number of lettersTime frame: From baseline to Week 26 treatment period, and 4 weeks safety follow up period.
  5. Low luminance visual acuity (LLVA)Time frame: From baseline to Week 26 treatment period
  6. Binocular reading speedTime frame: From baseline to Week 26 treatment period
  7. Binocular critical print sizeTime frame: From baseline to Week 26 treatment period
  8. NEI-VFQ scoreTime frame: From baseline to Week 26 treatment period

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.